Vitamin A Supplementation and Retinoic Acid Treatment in the Regulation of Antibody Responses In Vivo

Research output: Chapter in Book/Report/Conference proceedingChapter

37 Citations (Scopus)

Abstract

Vitamin A (VA, retinol) is essential for normal immune system maturation, but the effect of VA11Abbreviations: CI, confidence interval; DPT, diphtheria-pertussis-tetanus; EPI, Expanded Program on Immunization; IFN, interferon; IU, international unit; LPS, lipopolysaccharide; NK, natural killer; NKT, natural kill T-(Cell); OPV, oral polio vaccine; PBMC, peripheral blood mononuclear cell(s); PIC, polyriboinosinic acid:polyribocytidylic acid; RA, retinoic acid; TD, T-cell dependent; TI, T-cell independent; TNF, tumor necrosis factor; VA, vitamin A, WHO, World Health Organization. on antibody production, the hallmark of successful vaccination, is still not well understood. In countries where VA deficiency is a public health problem, many children worldwide are now receiving VA along with immunizations against poliovirus, measles, diphtheria, pertussis, and tetanus. The primary goal has been to provide enough VA to protect against the development of VA deficiency for a period of 4-6 months. However, it is also possible that VA might promote the vaccine antibody response. Several community studies, generally of small size, have been conducted in children supplemented with VA at the time of immunization, as promoted by the World Health Organization/UNICEF. However, only a few studies have reported differences in antibody titers or seroconversion rates due to VA. However, VA status was not directly assessed, and in some communities children were often breast fed, another strategy for preventing VA deficiency. Some of the vaccines used induced a high rate of seroconversion, even without VA. In children likely to have been VA deficient, oral polio vaccine seroconversion rate was increased by VA. In animal models, where VA status was controlled and VA deficiency confirmed, the antibody response to T-cell-dependent (TD) and polysaccharide antigens was significantly reduced, congruent with other defects in innate and adaptive immunity. Moreover, the active metabolite of VA, retinoic acid (RA) can potentiate antibody production to TD antigens in normal adult and neonatal animals. We speculate that numerous animal studies have correctly identified VA deficiency as a risk factor for low antibody production. A lack of effect of VA in human studies could be due to a low rate of VA deficiency in the populations studied or low sample numbers. The ability to detect differences in antibody response may also depend on the vaccine-adjuvant combination used. Future studies of VA supplementation and immunization should include assessment of VA status and a sufficiently large sample size. It would also be worthwhile to test the effect of neonatal VA supplementation on the response to immunization given after 6 months to 1 year of age, as VA supplementation, by preventing the onset of VA deficiency, may improve the response to immunizations given later on.

Original languageEnglish (US)
Title of host publicationVitamin A
EditorsGerald Litwack
Pages197-222
Number of pages26
DOIs
StatePublished - Mar 16 2007

Publication series

NameVitamins and Hormones
Volume75
ISSN (Print)0083-6729

Fingerprint

Tretinoin
Antibody Formation
Immunization
T-Lymphocytes
Vaccines
Vitamin A
Diphtheria
Whooping Cough
Tetanus
Poliomyelitis
Therapeutics
Newborn Animals
Combined Vaccines
Antigens
Immunization Programs
Poliovirus
United Nations
Measles
Adaptive Immunity
Innate Immunity

All Science Journal Classification (ASJC) codes

  • Physiology
  • Endocrinology

Cite this

Ross, A. Catharine. / Vitamin A Supplementation and Retinoic Acid Treatment in the Regulation of Antibody Responses In Vivo. Vitamin A. editor / Gerald Litwack. 2007. pp. 197-222 (Vitamins and Hormones).
@inbook{6bb2aaacafaa442d9be5659411dc5292,
title = "Vitamin A Supplementation and Retinoic Acid Treatment in the Regulation of Antibody Responses In Vivo",
abstract = "Vitamin A (VA, retinol) is essential for normal immune system maturation, but the effect of VA11Abbreviations: CI, confidence interval; DPT, diphtheria-pertussis-tetanus; EPI, Expanded Program on Immunization; IFN, interferon; IU, international unit; LPS, lipopolysaccharide; NK, natural killer; NKT, natural kill T-(Cell); OPV, oral polio vaccine; PBMC, peripheral blood mononuclear cell(s); PIC, polyriboinosinic acid:polyribocytidylic acid; RA, retinoic acid; TD, T-cell dependent; TI, T-cell independent; TNF, tumor necrosis factor; VA, vitamin A, WHO, World Health Organization. on antibody production, the hallmark of successful vaccination, is still not well understood. In countries where VA deficiency is a public health problem, many children worldwide are now receiving VA along with immunizations against poliovirus, measles, diphtheria, pertussis, and tetanus. The primary goal has been to provide enough VA to protect against the development of VA deficiency for a period of 4-6 months. However, it is also possible that VA might promote the vaccine antibody response. Several community studies, generally of small size, have been conducted in children supplemented with VA at the time of immunization, as promoted by the World Health Organization/UNICEF. However, only a few studies have reported differences in antibody titers or seroconversion rates due to VA. However, VA status was not directly assessed, and in some communities children were often breast fed, another strategy for preventing VA deficiency. Some of the vaccines used induced a high rate of seroconversion, even without VA. In children likely to have been VA deficient, oral polio vaccine seroconversion rate was increased by VA. In animal models, where VA status was controlled and VA deficiency confirmed, the antibody response to T-cell-dependent (TD) and polysaccharide antigens was significantly reduced, congruent with other defects in innate and adaptive immunity. Moreover, the active metabolite of VA, retinoic acid (RA) can potentiate antibody production to TD antigens in normal adult and neonatal animals. We speculate that numerous animal studies have correctly identified VA deficiency as a risk factor for low antibody production. A lack of effect of VA in human studies could be due to a low rate of VA deficiency in the populations studied or low sample numbers. The ability to detect differences in antibody response may also depend on the vaccine-adjuvant combination used. Future studies of VA supplementation and immunization should include assessment of VA status and a sufficiently large sample size. It would also be worthwhile to test the effect of neonatal VA supplementation on the response to immunization given after 6 months to 1 year of age, as VA supplementation, by preventing the onset of VA deficiency, may improve the response to immunizations given later on.",
author = "Ross, {A. Catharine}",
year = "2007",
month = "3",
day = "16",
doi = "10.1016/S0083-6729(06)75008-7",
language = "English (US)",
isbn = "0127098755",
series = "Vitamins and Hormones",
pages = "197--222",
editor = "Gerald Litwack",
booktitle = "Vitamin A",

}

Vitamin A Supplementation and Retinoic Acid Treatment in the Regulation of Antibody Responses In Vivo. / Ross, A. Catharine.

Vitamin A. ed. / Gerald Litwack. 2007. p. 197-222 (Vitamins and Hormones; Vol. 75).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Vitamin A Supplementation and Retinoic Acid Treatment in the Regulation of Antibody Responses In Vivo

AU - Ross, A. Catharine

PY - 2007/3/16

Y1 - 2007/3/16

N2 - Vitamin A (VA, retinol) is essential for normal immune system maturation, but the effect of VA11Abbreviations: CI, confidence interval; DPT, diphtheria-pertussis-tetanus; EPI, Expanded Program on Immunization; IFN, interferon; IU, international unit; LPS, lipopolysaccharide; NK, natural killer; NKT, natural kill T-(Cell); OPV, oral polio vaccine; PBMC, peripheral blood mononuclear cell(s); PIC, polyriboinosinic acid:polyribocytidylic acid; RA, retinoic acid; TD, T-cell dependent; TI, T-cell independent; TNF, tumor necrosis factor; VA, vitamin A, WHO, World Health Organization. on antibody production, the hallmark of successful vaccination, is still not well understood. In countries where VA deficiency is a public health problem, many children worldwide are now receiving VA along with immunizations against poliovirus, measles, diphtheria, pertussis, and tetanus. The primary goal has been to provide enough VA to protect against the development of VA deficiency for a period of 4-6 months. However, it is also possible that VA might promote the vaccine antibody response. Several community studies, generally of small size, have been conducted in children supplemented with VA at the time of immunization, as promoted by the World Health Organization/UNICEF. However, only a few studies have reported differences in antibody titers or seroconversion rates due to VA. However, VA status was not directly assessed, and in some communities children were often breast fed, another strategy for preventing VA deficiency. Some of the vaccines used induced a high rate of seroconversion, even without VA. In children likely to have been VA deficient, oral polio vaccine seroconversion rate was increased by VA. In animal models, where VA status was controlled and VA deficiency confirmed, the antibody response to T-cell-dependent (TD) and polysaccharide antigens was significantly reduced, congruent with other defects in innate and adaptive immunity. Moreover, the active metabolite of VA, retinoic acid (RA) can potentiate antibody production to TD antigens in normal adult and neonatal animals. We speculate that numerous animal studies have correctly identified VA deficiency as a risk factor for low antibody production. A lack of effect of VA in human studies could be due to a low rate of VA deficiency in the populations studied or low sample numbers. The ability to detect differences in antibody response may also depend on the vaccine-adjuvant combination used. Future studies of VA supplementation and immunization should include assessment of VA status and a sufficiently large sample size. It would also be worthwhile to test the effect of neonatal VA supplementation on the response to immunization given after 6 months to 1 year of age, as VA supplementation, by preventing the onset of VA deficiency, may improve the response to immunizations given later on.

AB - Vitamin A (VA, retinol) is essential for normal immune system maturation, but the effect of VA11Abbreviations: CI, confidence interval; DPT, diphtheria-pertussis-tetanus; EPI, Expanded Program on Immunization; IFN, interferon; IU, international unit; LPS, lipopolysaccharide; NK, natural killer; NKT, natural kill T-(Cell); OPV, oral polio vaccine; PBMC, peripheral blood mononuclear cell(s); PIC, polyriboinosinic acid:polyribocytidylic acid; RA, retinoic acid; TD, T-cell dependent; TI, T-cell independent; TNF, tumor necrosis factor; VA, vitamin A, WHO, World Health Organization. on antibody production, the hallmark of successful vaccination, is still not well understood. In countries where VA deficiency is a public health problem, many children worldwide are now receiving VA along with immunizations against poliovirus, measles, diphtheria, pertussis, and tetanus. The primary goal has been to provide enough VA to protect against the development of VA deficiency for a period of 4-6 months. However, it is also possible that VA might promote the vaccine antibody response. Several community studies, generally of small size, have been conducted in children supplemented with VA at the time of immunization, as promoted by the World Health Organization/UNICEF. However, only a few studies have reported differences in antibody titers or seroconversion rates due to VA. However, VA status was not directly assessed, and in some communities children were often breast fed, another strategy for preventing VA deficiency. Some of the vaccines used induced a high rate of seroconversion, even without VA. In children likely to have been VA deficient, oral polio vaccine seroconversion rate was increased by VA. In animal models, where VA status was controlled and VA deficiency confirmed, the antibody response to T-cell-dependent (TD) and polysaccharide antigens was significantly reduced, congruent with other defects in innate and adaptive immunity. Moreover, the active metabolite of VA, retinoic acid (RA) can potentiate antibody production to TD antigens in normal adult and neonatal animals. We speculate that numerous animal studies have correctly identified VA deficiency as a risk factor for low antibody production. A lack of effect of VA in human studies could be due to a low rate of VA deficiency in the populations studied or low sample numbers. The ability to detect differences in antibody response may also depend on the vaccine-adjuvant combination used. Future studies of VA supplementation and immunization should include assessment of VA status and a sufficiently large sample size. It would also be worthwhile to test the effect of neonatal VA supplementation on the response to immunization given after 6 months to 1 year of age, as VA supplementation, by preventing the onset of VA deficiency, may improve the response to immunizations given later on.

UR - http://www.scopus.com/inward/record.url?scp=33947163299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947163299&partnerID=8YFLogxK

U2 - 10.1016/S0083-6729(06)75008-7

DO - 10.1016/S0083-6729(06)75008-7

M3 - Chapter

C2 - 17368317

AN - SCOPUS:33947163299

SN - 0127098755

SN - 9780127098753

T3 - Vitamins and Hormones

SP - 197

EP - 222

BT - Vitamin A

A2 - Litwack, Gerald

ER -